0190 #2

0107



OIPE

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: US/09/904,117 TIME: 17:44:39

Input Set : N:\Crf3\RULE60\09904117.raw
Output Set: N:\CRF3\01172002\I904117.raw

ENTERED

```
1 <110> APPLICANT: MUIR, TOM W.
2       COLE, PHILIP A
3       FRIEDMAN, JEFFREY M.
4       SONDHI, DOLAN
5       SEVERINOV, KONSTANITINE
6 <120> TITLE OF INVENTION: METHODS OF LIGATING EXPRESSED PROTEINS
7 <130> FILE REFERENCE: 600-1-214CIPB
8 <140> CURRENT APPLICATION NUMBER: 09/904,117
9 <141> CURRENT FILING DATE: 2001-07-12
11 <150> PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/191,890
W--> 12 <151> PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-13
14 <150> PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/093,990
W--> 15 <151> PRIOR FILING DATE: EARLIER FILING DATE: 1998-07-24
16 <160> NUMBER OF SEQ ID NOS: 11
17 <170> SOFTWARE: PatentIn Ver. 2.0
19 <210> SEQ ID NO: 1
20 <211> LENGTH: 162
21 <212> TYPE: PRT
22 <213> ORGANISM: Artificial Sequence
23 <220> FEATURE:
24 <223> OTHER INFORMATION: Description of Artificial Sequence: generated by
25       ligation of two proteins under certain conditions
26 <400> SEQUENCE: 1
27       Met Leu Phe Val Ala Leu Tyr Asp Phe Val Ala Ser Gly Asp Asn Thr
28         1               5                  10                  15
29       Leu Ser Ile Thr Lys Gly Glu Lys Leu Arg Val Leu Gly Tyr Asn His
30                    20                  25                  30
31       Asn Gly Glu Trp Ala Glu Ala Gln Thr Lys Asn Gly Gln Gly Trp Val
32                35                  40                  45
33       Pro Ser Asn Tyr Ile Thr Pro Val Gly Cys Leu Glu Lys His Ser Trp
34            50                  55                  60
35       Tyr His Gly Pro Val Ser Arg Asn Ala Ala Glu Tyr Leu Leu Ser Ser
36        65                  70                  75                  80
37       Gly Ile Asn Gly Ser Phe Leu Val Arg Glu Ser Glu Ser Ser Pro Gly
38                        85                  90                  95
39       Gln Arg Ser Ile Ser Leu Arg Tyr Glu Gly Arg Val Tyr His Tyr Arg
40                   100                 105                 110
41       Ile Asn Thr Ala Ser Asp Gly Lys Leu Tyr Val Ser Ser Glu Ser Arg
42              115                 120                 125
43       Phe Asn Thr Leu Ala Glu Leu Val His His His Ser Thr Val Ala Asp
44          130                 135                 140
45       Gly Leu Ile Thr Thr Leu His Tyr Pro Ala Pro Lys Arg Gly Ile His
46       145                 150                 155                 160
```

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: **US/09/904,117** TIME: 17:44:39

Input Set : **N:\Crf3\RULE60\09904117.raw**
Output Set: **N:\CRF3\01172002\I904117.raw**

47 Arg Asp
49 <210> SEQ ID NO: 2
50 <211> LENGTH: 12
51 <212> TYPE: PRT
52 <213> ORGANISM: Artificial Sequence
53 <220> FEATURE:
54 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
55 synthesized by solid phase peptide synthesis.
56 <220> FEATURE:
57 <221> NAME/KEY: SITE
58 <222> LOCATION: (11)
59 <223> OTHER INFORMATION: Xaa(position 11) is aminocaproate.
60 <220> FEATURE:
61 <223> OTHER INFORMATION: C-terminal K has a fluorescein moiety off the
62 E-NH2 group.
63 <400> SEQUENCE: 2
W--> 64 **Cys Glu Asp Asn Glu Tyr Thr Ala Arg Glu Xaa Lys**
65 **1 5 10**
67 <210> SEQ ID NO: 3
68 <211> LENGTH: 12
69 <212> TYPE: PRT
70 <213> ORGANISM: Artificial Sequence
71 <220> FEATURE:
72 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
73 synthesized by solid phase peptide synthesis.
74 <220> FEATURE:
75 <221> NAME/KEY: SITE
76 <222> LOCATION: (11)
77 <223> OTHER INFORMATION: Xaa(position 11) is aminocaproate.
78 <400> SEQUENCE: 3
W--> 79 **Cys Glu Asp Asn Glu Tyr Thr Ala Arg Glu Xaa Lys**
80 **1 5 10**
82 <210> SEQ ID NO: 4
83 <211> LENGTH: 8
84 <212> TYPE: PRT
85 <213> ORGANISM: Artificial Sequence
86 <220> FEATURE:
87 <223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide
88 synthesized by solid phase peptide synthesis.
89 <220> FEATURE:
90 <223> OTHER INFORMATION: K has a fluorescein moiety off the E-NH2 group; C-
91 terminus is an amide group.
92 <400> SEQUENCE: 4
93 Cys Gly Arg Gly Arg Gly Arg Lys
94 1 5
96 <210> SEQ ID NO: 5
97 <211> LENGTH: 8
98 <212> TYPE: PRT
99 <213> ORGANISM: Unknown

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: **US/09/904,117** TIME: 17:44:39

Input Set : **N:\Crf3\RULE60\09904117.raw**
Output Set: **N:\CRF3\01172002\I904117.raw**

<220> FEATURE:
<223> OTHER INFORMATION: Description of Unknown Organism: ligand
<400> SEQUENCE: 5
Pro Val Pro Tyr Glu Asn Val Gly
1 5
<210> SEQ ID NO: 6
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Model peptide synthesized by solid phase peptide synthesis.
<220> FEATURE:
<223> OTHER INFORMATION: C-terminus is an amide group.
<400> SEQUENCE: 6
Pro Pro Ala Tyr Pro Pro Pro Pro Val Pro Lys
1 5 10
<210> SEQ ID NO: 7
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
<400> SEQUENCE: 7
ccggtcatcg aaggtcgttg cctggagaaa cattcctggt at 42
<210> SEQ ID NO: 8
<211> LENGTH: 41
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
<400> SEQUENCE: 8
catgatacca ggaatgtttc tccaggcaac gaccttcgat g 41
<210> SEQ ID NO: 9
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: motif within linker region
<400> SEQUENCE: 9
Ile Glu Gly Arg Cys
1 5
<210> SEQ ID NO: 10
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: US/09/904,117 TIME: 17:44:39

Input Set : N:\Crf3\RULE60\09904117.raw
Output Set: N:\CRF3\01172002\I904117.raw

154 <220> FEATURE:
155 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
156 oligonucleotide
157 <400> SEQUENCE: 10
158 ggatcccctg gtcatatgct ttttgtggca ctctatgatt ttgtg 45
160 <210> SEQ ID NO: 11
161 <211> LENGTH: 42
162 <212> TYPE: DNA
163 <213> ORGANISM: Artificial Sequence
164 <220> FEATURE:
165 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
166 oligonucleotide
167 <400> SEQUENCE: 11
168 atgtttctcc aggctgttaa cgggggtgat gtagttgctt gg 42

VERIFICATION SUMMARY DATE: 01/17/2002
PATENT APPLICATION: **US/09/904,117** TIME: 17:44:40

Input Set : **N:\Crf3\RULE60\09904117.raw**
Output Set: **N:\CRF3\01172002\I904117.raw**

L:12 M:256 W: Invalid Numeric Header Field, Wrong Prior FILING DATE:YYYY-MM-DD
L:15 M:256 W: Invalid Numeric Header Field, Wrong Prior FILING DATE:YYYY-MM-DD
L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:79 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3